

**Table S1: Duration between Last Reported NAT testing and recovery date and COVID pandemic periods**

	7/22/2020- 12/31/2020, n (%)	1/1/2021-6/30/2021, n (%)	7/1/2021-9/28/2021, n (%)	Total, n (%)
NAT 0-7 days	5 (38.5)	34 (60.7)	55 (67.9)	94 (62.7)
NAT 8-21 days	0 (0.0)	4 (7.1)	13 (16.1)	17 (11.3)
NAT 29-367 days	8 (61.5)	18 (32.1)	13 (16.1)	39 (26)
Total	13 (100)	56 (100)	81 (100)	150 (100)

NAT: Nucleic Acid Test

**Table S2:** Utilization of COVID-19 NAT positive deceased donors including multiorgan transplants

Deceased donors N=150	Days between Last Reported NAT testing and organ recovery: 0-367 days (Whole cohort)		
Organs, n (%)	Number of organs recovered, n	Number of organs transplanted, n (%)	Number of organs discarded, n (%)
Kidney	295	193(65.4) <sup>a</sup>	102 (34.6)
Pancreas	5	5 (100.0) <sup>a</sup>	0 (0.0)
Heart	18	18 (100) <sup>a</sup>	0 (0.0)
Lungs	3	3 (100) <sup>b</sup>	0 (0.0)
Liver	64	57 (89.0) <sup>a</sup>	7 (11.0)
Intestine	0	0	0
Total n (%) <sup>a</sup>	385	276 (71.6)	109 (28.4)
Deceased donors N=94 (94/150=62.7%)	Days between NAT testing and organ recovery: 0-7 days		
Organs, n (%)	Number of organs recovered, n	Number of organs transplanted, n (%)	Number of organs discarded, n (%)
Kidney	183	119 (65.0)	64 (35.0)
Pancreas	4	4 (100.0)	0 (0.0)
Heart	12	12 (100)	0 (0.0)
Lungs	3	3 (100)	0 (0.0)
Liver	44	40 (90.0)	4 (10.0)
Total <sup>a</sup> n (%)	246	178 (72.4)	68 (27.6)
Deceased donors N=17 (17/150=11.3%)	Days between NAT testing and organ recovery: 8-28 days		
Organs, n (%)	Number of organs recovered, n	Number of organs transplanted, n (%)	Number of organs discarded, n (%)
Kidney	34	23 (67.6)	11 (32.4)
Pancreas	0	0 (0.0)	0 (0.0)

Heart	2	2 (100)	0 (0.0)
Lungs	0	0 (0.0)	0 (0.0)
Liver	9	8 (89.9)	1 (11.1)
Total <sup>a</sup> n (%)	45	33 (73.3)	12 (26.7)
Deceased donors N=39 (39/150=26.0%))	Days between NAT testing and organ recovery: 29-367 days		
Organs, n (%)	Number of organs recovered, n (%)	Number of organs transplanted, n (%)	Number of organs discarded, n (%)
Kidney	78	51 (75.4)	27 (34.6)
Pancreas	1	1 (100.0)	0 (0.0)
Heart	4	4 (100.0)	0 (0.0)
Lungs	0	0 (0.0)	0 (0.0)
Liver	11	9 (81.8)	2 (18.2)
Total <sup>a</sup> n (%)	94	65 (69.2)	29 (30.8)

<sup>a</sup>Includes combined organ transplantation.

<sup>b</sup>One single lung and 1 double lung recovery. SPK= Simultaneous pancreas kidney; Simultaneous liver kidney= SLK; Simultaneous heart kidney= SHK.

**Table S3. Posttransplant main outcomes of donor COVID NAT positive solid organ transplants between July 22, 2020, and September 29, 2021.**

SPK= Simultaneous pancreas kidney; SLK = Simultaneous liver kidney; SHK = Simultaneous heart kidney

SOT	Time from transplant date to the study censoring date (9/30/2021), days, median (IQR)	Reported overall graft failure (including graft failure and death), n	Reported mortality, n	Reported time to graft failure (graft failure date-transplant date), days	Reported time to death (death date – transplant date), days
Kidney alone, n=180					
Single, n=178	75 (23, 149)	5	2	0, 0, 66	31, 109
En-bloc, n=1	64	0	0	n/a	n/a
Sequential, n=1	239	0	0	n/a	n/a
Liver alone, n=53	107 (46, 196)	3	3	4, 6, 85	4, 6, 85
Heart alone, n=15	144 (68, 243)	0	0	n/a	n/a
Lung alone, n=2	107, 204	0	0	n/a	n/a
Combined organ transplantation					
SPK (n=5)	124 (107, 145)	0	0	n/a	n/a
SLK (n=4)	104 (102, 205)	0	0	n/a	n/a
SHK (n=3)	62 (33, 145)	0	0	n/a	n/a

**Table S4. Kidney alone recipient and transplant characteristics between July 22, 2020 and September 30, 2021**

<b>Kidney Alone Recipients Characteristics (Transplants between 8/6/2020 and 9/29/2021)</b>	<b>Value</b>
N	180
Age (years) – mean (SD)	52 (14)
Male Sex – n (%)	107 (59)
BMI (kg/m <sup>2</sup> )-mean (SD)	28 (6)
Total days on waitlist Median (IQR)	512 (171-1106)
Black Race- n (%)	50 (28)
Dialysis at time of transplant-n (%)	131 (73)
Previous kidney transplant (%)	13 (7)
Diabetes (%)	58 (32)
Calculated EPTS (%) - mean (SD)	42 (29)
cPRA%, median (IQR)	0 (0-15)
<b>Transplant factors</b>	
CIT hours, median (IQR) (n=149)	20.8 (16.3, 25.8)
Pumped % (n=158)	120 (76)
HLA mismatch, median (IQR)	4 (3, 5)
ECD donor (%)	15 (8)
KDPI (%), median (IQR)	41 (19, 59)
PHS high risk donor (%)	25 (14)
Share type	
Local	75 (42)
Regional	34 (19)
National	71 (39)
<b>Recipient Immunosuppression</b>	

Induction (N=180)- n (%)	
Thymoglobulin	113 (62.8)
Basiliximab	24 (13.3)
No induction	43 (23.9)
Maintenance immunosuppression at transplant hospitalization discharge- n (%)	
Tacrolimus	120 (66.7)
Mycophenolate	144 (80.0)
Steroids	127 (70.6)
Belatacept	
<b>Recipient Outcomes</b>	
Discharge creatinine (mg/dl)-median (IQR), (n=147)	4.8 (2.4, 7.8)
Length of hospital stay from transplant to discharge-(days)-median (IQR), (n=145)	4 (3, 5)
Delayed graft function-n (%), (n=147)	36 (24)
Posttransplant overall graft failure rate during study period, % (n=149)	3.4 (5/149)
Patient survival rate during study period, % (n=149)	98.7 (2/149)
Resumed chronic hemodialysis, n (%)	1 (0.6)
Cause of kidney graft failure	
Vascular thrombosis	2 (post-op day # 0)
Recurrent disease	1 (post-op day # 66)
Cause of kidney recipient death	
Respiratory failure	1 (post-op day # 109)
Other	1 (post-op day # 31)

BMI: Body mass index; EPTS: Estimated posttransplant survival; cPRA: Calculated panel reactive antibody; CIT: Cold ischemia time; ECD: Extended-criteria donor; PHS: Public health service

